Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18.
Choi DH, Kim M, Kim YS, Park KU, Cho JH, Kim H, Lee KH, Ahn H, Kim IH, Lee KH, Lee GW, Yi SY, Ahn BC, Lee MY, Jung HA, Park S, Sun JM, Ahn JS, Lee SH, Ahn MJ.
Choi DH, et al. Among authors: sun jm.
JTO Clin Res Rep. 2024 Oct 16;5(12):100734. doi: 10.1016/j.jtocrr.2024.100734. eCollection 2024 Dec.
JTO Clin Res Rep. 2024.
PMID: 39619275
Free PMC article.